Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geptanolimab + Fruquintinib in EGFR-mutated NSCLC
NCT03976856Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Jul 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of geptanolimab in non-small cell lung cancer (NSCLC), sponsored by Genor Biopharma. Primary endpoints: Incidence of Adverse Event, Incidence of Serious Adverse Event and 2 more. Status: unknown.
02
Drugs
geptanolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03976856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976856.